The FDA has approved mirikizumab-mrkz (Omvoh, Lilly) for the treatment of moderate to severe ulcerative colitis in adults. The drug is the first UC medication to target the p19 subunit of interleukin-23.
The approval was based on results from the LUCENT program, which evaluated the efficacy and safety of mirikizumab in adults with moderate to severe UC. All patients in the LUCENT program had past treatment that did not work, stopped working or that they could not tolerate. The program included